Core Viewpoint - The company has approved the use of idle self-owned funds amounting to 50 million RMB to purchase financial products, aiming to enhance the efficiency of fund utilization while ensuring operational needs and fund safety [1][4]. Group 1: Investment Details - The company signed a contract with Founder Zhongqi Futures Co., Ltd. for the "Founder Zhongqi Xin'an No. 1 Collective Asset Management Plan" with a principal amount of 50 million RMB [1]. - The expected annualized return on the investment is 3.60% [1]. - The investment will focus on fixed-income products, including bank deposits, cash, money market funds, and various types of bonds [1]. Group 2: Risk Management - The finance department will monitor financial market changes and assess potential adverse impacts on the investment products [4]. - The internal audit department will track the investment direction and may conduct audits on the use and custody of the invested funds [4]. - Independent directors and the supervisory board have the authority to conduct regular or ad-hoc checks on the investment products [4]. Group 3: Impact on Operations - The investment of 50 million RMB in financial products will not adversely affect the company's operational needs and is expected to improve the efficiency and return of idle funds, thereby enhancing overall performance and safeguarding shareholder interests [5].

截至2025年5月16日收盘，益盛药业(002566)报收于7.36元，上涨2.36%，换手率4.89%，成交量11.34万 手，成交额8297.03万元。 当日关注点 交易信息汇总 5月16日，益盛药业的资金流向情况如下：- 主力资金净流入1189.27万元；- 游资资金净流出305.99万 元；- 散户资金净流出883.28万元。 公司公告汇总2024年年度权益分派实施公告 益盛药业2024年度利润分配方案已获2025年5月9日召开的2024年年度股东大会审议通过。具体方案 为：- 以截至2024年12月31日的公司总股本330,951,600股为基数，向全体股东每10股派发现金红利人民 币1.00元（含税），合计派发现金红利人民币33,095,160.00元；- 不送红股，不以资本公积金转增股 本；- 权益分派股权登记日为2025年5月21日，除权除息日为2025年5月22日；- 分派对象为截止2025年5 月21日下午深圳证券交易所收市后，在中国结算深圳分公司登记在册的本公司全体股东；- A股股东现 金红利将于2025年5月22日通过股东托管证券公司直接划入其资金账户。 关于使用闲置自有资金购买理财产 ...